PIK3CA E545Q

CI-VAR-00000780Explore in graph →NP_006209.2:p.Glu545GlnNM_006218.3:c.1633G>CClinVar 375896 CIViC 881 rs104886003

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
PIK3CA E545Q	PI103	Predictive	D	Supports Sensitivity Response	—	submitted	EID2046 In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC) PMID 19513541 · Zou et al., 2009 · Open in CIViC	civic
Malignant Breast Neoplasm1
PIK3CA E545K OR PIK3CA E545Q OR PIK3CA E545A OR PIK3CA E545G OR PIK3CA E545V OR PIK3CA E545D OR PIK3CA E545L OR PIK3CA E545R	Fulvestrant + Inavolisib + PalbociclibCombination	Predictive	A	Supports Sensitivity Response	3	accepted

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
375896	drug response	no assertion criteria provided	0	Histone Methylation Therapy response; Neoplasm	somatic	2	Nov 27, 2017	clinvar

Malignant Colorectal Neoplasm1
PIK3CA E545Q	Cetuximab + IrinotecanCombination	Predictive	C	Does Not Support Resistance	3	accepted	EID2213 Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E545Q (exon 10), were wildtype for NRAS, B… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic

HER2 Negative Breast Cancer1unmapped disease
PIK3CA E545Q	Capivasertib + FulvestrantCombination	Predictive	A	Supports Sensitivity Response	2	submitted	EID12187 In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC	civic